Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2012

01-07-2012

Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus

Authors: S. Michael Gharacholou, Brenda J. Larson, Christian C. Zuver, Ryan J. Wubben, Giorgio Gimelli, Amish N. Raval

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2012

Login to get access

Abstract

Strong evidence exists in favor of rapid transfer of a patient suffering an ST-elevation myocardial infarction (STEMI) to the nearest hospital with primary percutaneous coronary intervention (PCI) capability, assuming the time from first medical contact to balloon inflation can be achieved in less than 90 min. In many areas, PCI hospitals have successfully collaborated with regional non-PCI hospitals to provide primary PCI for STEMI; however, significant variations exist in how these programs are executed. For example, the pre PCI hospital administration of antithrombotic agents by emergency medical personnel can include aspirin, clopidogrel, unfractionated heparin, low molecular weight heparin, partial or full dose fibrinolytics or combinations thereof. There is little consensus on the optimal cocktail, dose and route of administration. Standardizing the pre PCI antithrombotic regimen across hospital systems may be one approach to improve timely administration of these therapies, and potentially improve STEMI outcomes.
Literature
1.
go back to reference Antman EM, Anbe DT, Armstrong PW et al (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110:e82–292PubMedCrossRef Antman EM, Anbe DT, Armstrong PW et al (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110:e82–292PubMedCrossRef
2.
go back to reference Jacobs AK, Antman EM, Faxon DP, Gregory T, Solis P (2007) Development of systems of care for ST-elevation myocardial infarction patients: executive summary. Circulation 116:217–230PubMedCrossRef Jacobs AK, Antman EM, Faxon DP, Gregory T, Solis P (2007) Development of systems of care for ST-elevation myocardial infarction patients: executive summary. Circulation 116:217–230PubMedCrossRef
3.
go back to reference Gharacholou SM, Alexander KP, Chen AY et al (2010) Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative. Am Heart J 159:757–763PubMedCrossRef Gharacholou SM, Alexander KP, Chen AY et al (2010) Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative. Am Heart J 159:757–763PubMedCrossRef
4.
go back to reference Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J (2002) Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 359:373–377PubMedCrossRef Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J (2002) Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 359:373–377PubMedCrossRef
5.
go back to reference Grzybowski M, Clements EA, Parsons L et al (2003) Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 290:1891–1898PubMedCrossRef Grzybowski M, Clements EA, Parsons L et al (2003) Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 290:1891–1898PubMedCrossRef
6.
go back to reference Boden WE, Eagle K, Granger CB (2007) Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. J Am Coll Cardiol 50:917–929PubMedCrossRef Boden WE, Eagle K, Granger CB (2007) Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. J Am Coll Cardiol 50:917–929PubMedCrossRef
7.
go back to reference Jacobs AK, Antman EM, Ellrodt G et al (2006) Recommendation to develop strategies to increase the number of ST-segment-elevation myocardial infarction patients with timely access to primary percutaneous coronary intervention. Circulation 113:2152–2163PubMedCrossRef Jacobs AK, Antman EM, Ellrodt G et al (2006) Recommendation to develop strategies to increase the number of ST-segment-elevation myocardial infarction patients with timely access to primary percutaneous coronary intervention. Circulation 113:2152–2163PubMedCrossRef
8.
go back to reference Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA (2008) Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:708S–775SPubMedCrossRef Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA (2008) Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:708S–775SPubMedCrossRef
9.
go back to reference Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29:2909–2945PubMedCrossRef Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29:2909–2945PubMedCrossRef
10.
go back to reference Cantor WJ, Fitchett D, Borgundvaag B et al (2009) Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 360:2705–2718PubMedCrossRef Cantor WJ, Fitchett D, Borgundvaag B et al (2009) Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 360:2705–2718PubMedCrossRef
12.
go back to reference Eisenberg MJ, Topal EJ (1996) Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Arch Intern Med 156:1506–1510PubMedCrossRef Eisenberg MJ, Topal EJ (1996) Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Arch Intern Med 156:1506–1510PubMedCrossRef
13.
go back to reference ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349–360 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349–360
14.
go back to reference Heestermans T, van ’t Hof AW, ten Berg JM et al (2010) The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy. Am Heart J 160:1079–1084PubMedCrossRef Heestermans T, van ’t Hof AW, ten Berg JM et al (2010) The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy. Am Heart J 160:1079–1084PubMedCrossRef
15.
go back to reference Berger JS, Stebbins A, Granger CB et al (2008) Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation 117:192–199PubMedCrossRef Berger JS, Stebbins A, Granger CB et al (2008) Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation 117:192–199PubMedCrossRef
16.
go back to reference Mehta SR, Bassand JP, Chrolavicius S et al (2010) Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363:930–942PubMedCrossRef Mehta SR, Bassand JP, Chrolavicius S et al (2010) Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363:930–942PubMedCrossRef
17.
go back to reference Mehta SR, Tanguay JF, Eikelboom JW et al (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376:1233–1243PubMedCrossRef Mehta SR, Tanguay JF, Eikelboom JW et al (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376:1233–1243PubMedCrossRef
18.
go back to reference Pollack CV Jr, Antman EM, Hollander JE (2008) 2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med 52(344–355):e341 Pollack CV Jr, Antman EM, Hollander JE (2008) 2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med 52(344–355):e341
19.
go back to reference Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533PubMedCrossRef Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533PubMedCrossRef
20.
go back to reference Leon MB, Baim DS, Popma JJ et al (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339:1665–1671PubMedCrossRef Leon MB, Baim DS, Popma JJ et al (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339:1665–1671PubMedCrossRef
21.
go back to reference Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502PubMedCrossRef Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502PubMedCrossRef
22.
go back to reference Chen ZM, Jiang LX, Chen YP et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621PubMedCrossRef Chen ZM, Jiang LX, Chen YP et al (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621PubMedCrossRef
23.
go back to reference Sabatine MS, Cannon CP, Gibson CM et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179–1189PubMedCrossRef Sabatine MS, Cannon CP, Gibson CM et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179–1189PubMedCrossRef
24.
go back to reference Scirica BM, Sabatine MS, Morrow DA et al (2006) The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol 48:37–42PubMedCrossRef Scirica BM, Sabatine MS, Morrow DA et al (2006) The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol 48:37–42PubMedCrossRef
25.
go back to reference Sabatine MS, Cannon CP, Gibson CM et al (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294:1224–1232PubMedCrossRef Sabatine MS, Cannon CP, Gibson CM et al (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294:1224–1232PubMedCrossRef
26.
go back to reference Antman EM, Hand M, Armstrong PW et al (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117:296–329PubMedCrossRef Antman EM, Hand M, Armstrong PW et al (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117:296–329PubMedCrossRef
27.
go back to reference Kushner FG, Hand M, Smith SC Jr et al (2009) 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54:2205–2241PubMedCrossRef Kushner FG, Hand M, Smith SC Jr et al (2009) 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54:2205–2241PubMedCrossRef
28.
go back to reference Levine GN, Bates ER, Blankenship JC et al (2011) ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58:e44–122PubMedCrossRef Levine GN, Bates ER, Blankenship JC et al (2011) ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58:e44–122PubMedCrossRef
29.
go back to reference Mangiacapra F, Muller O, Ntalianis A et al (2010) Comparison of 600 versus 300-mg clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 106:1208–1211PubMedCrossRef Mangiacapra F, Muller O, Ntalianis A et al (2010) Comparison of 600 versus 300-mg clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 106:1208–1211PubMedCrossRef
30.
go back to reference Alexander KP, Chen AY, Roe MT et al (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294:3108–3116PubMedCrossRef Alexander KP, Chen AY, Roe MT et al (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294:3108–3116PubMedCrossRef
31.
go back to reference Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119:2553–2560PubMedCrossRef Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119:2553–2560PubMedCrossRef
32.
go back to reference Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O’Gara PT, Stein CM (2010) ACCF/AHA Clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 122:537–557PubMedCrossRef Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O’Gara PT, Stein CM (2010) ACCF/AHA Clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 122:537–557PubMedCrossRef
33.
go back to reference Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS (2009) Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 53:1273–1278PubMedCrossRef Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS (2009) Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 53:1273–1278PubMedCrossRef
34.
go back to reference Gilard M, Arnaud B, Cornily JC et al (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256–260PubMedCrossRef Gilard M, Arnaud B, Cornily JC et al (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256–260PubMedCrossRef
35.
go back to reference Shuldiner AR, O’Connell JR, Bliden KP et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849–857PubMedCrossRef Shuldiner AR, O’Connell JR, Bliden KP et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849–857PubMedCrossRef
36.
go back to reference Small DS, Farid NA, Payne CD et al (2010) Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 49:777–798PubMedCrossRef Small DS, Farid NA, Payne CD et al (2010) Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 49:777–798PubMedCrossRef
37.
go back to reference Farid NA, Smith RL, Gillespie TA et al (2007) The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 35:1096–1104PubMedCrossRef Farid NA, Smith RL, Gillespie TA et al (2007) The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 35:1096–1104PubMedCrossRef
38.
go back to reference Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015PubMedCrossRef Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015PubMedCrossRef
39.
go back to reference Serebruany VL (2011) Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook. Cardiovasc Revasc Med 12:94–98PubMedCrossRef Serebruany VL (2011) Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook. Cardiovasc Revasc Med 12:94–98PubMedCrossRef
40.
go back to reference Bhatt DL (2007) Intensifying platelet inhibition—navigating between Scylla and Charybdis. N Engl J Med 357:2078–2081PubMedCrossRef Bhatt DL (2007) Intensifying platelet inhibition—navigating between Scylla and Charybdis. N Engl J Med 357:2078–2081PubMedCrossRef
41.
go back to reference Teng R, Oliver S, Hayes MA, Butler K (2010) Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 38:1514–1521PubMedCrossRef Teng R, Oliver S, Hayes MA, Butler K (2010) Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 38:1514–1521PubMedCrossRef
42.
go back to reference Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057PubMedCrossRef Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057PubMedCrossRef
43.
go back to reference Steg PG, James S, Harrington RA et al (2010) Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122:2131–2141PubMedCrossRef Steg PG, James S, Harrington RA et al (2010) Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122:2131–2141PubMedCrossRef
44.
go back to reference Cannon CP (2000) Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. Clin Cardiol 23(Suppl 6):VI-14–VI-17 Cannon CP (2000) Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. Clin Cardiol 23(Suppl 6):VI-14–VI-17
45.
go back to reference Ottani F, La Vecchia L, De Vita M, Catapano O, Tarantino F, Galvani M (2010) Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 106(167–174):e161 Ottani F, La Vecchia L, De Vita M, Catapano O, Tarantino F, Galvani M (2010) Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 106(167–174):e161
46.
go back to reference Mehilli J, Kastrati A, Schulz S et al (2009) Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119:1933–1940PubMedCrossRef Mehilli J, Kastrati A, Schulz S et al (2009) Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119:1933–1940PubMedCrossRef
47.
go back to reference Ellis SG, Tendera M, de Belder MA et al (2008) Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358:2205–2217PubMedCrossRef Ellis SG, Tendera M, de Belder MA et al (2008) Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358:2205–2217PubMedCrossRef
48.
go back to reference Henry TD, Sharkey SW, Burke MN et al (2007) A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 116:721–728PubMedCrossRef Henry TD, Sharkey SW, Burke MN et al (2007) A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 116:721–728PubMedCrossRef
49.
go back to reference Keeley EC, Boura JA, Grines CL (2006) Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 367:579–588PubMedCrossRef Keeley EC, Boura JA, Grines CL (2006) Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 367:579–588PubMedCrossRef
50.
go back to reference Investigtors A-P (2006) Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367:569–578CrossRef Investigtors A-P (2006) Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367:569–578CrossRef
51.
go back to reference Gharacholou SM, Lopes RD, Washam JB, Newby LK, James SK, Alexander JH (2010) Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. J Thromb Thrombolysis 29:516–528PubMedCrossRef Gharacholou SM, Lopes RD, Washam JB, Newby LK, James SK, Alexander JH (2010) Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. J Thromb Thrombolysis 29:516–528PubMedCrossRef
52.
go back to reference Mahaffey KW, Granger CB, Collins R et al (1996) Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 77:551–556PubMedCrossRef Mahaffey KW, Granger CB, Collins R et al (1996) Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 77:551–556PubMedCrossRef
53.
go back to reference Antman EM, Hand M, Armstrong PW et al (2008) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51:210–247PubMedCrossRef Antman EM, Hand M, Armstrong PW et al (2008) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51:210–247PubMedCrossRef
54.
go back to reference Antman EM, Morrow DA, McCabe CH et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:1477–1488PubMedCrossRef Antman EM, Morrow DA, McCabe CH et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:1477–1488PubMedCrossRef
55.
go back to reference Yusuf S, Mehta SR, Chrolavicius S et al (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519–1530PubMedCrossRef Yusuf S, Mehta SR, Chrolavicius S et al (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519–1530PubMedCrossRef
56.
go back to reference Stone GW, Witzenbichler B, Guagliumi G et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218–2230PubMedCrossRef Stone GW, Witzenbichler B, Guagliumi G et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218–2230PubMedCrossRef
57.
go back to reference Dangas GD, Mehran R, Nikolsky E et al (2011) Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. J Am Coll Cardiol 57:2309–2316PubMedCrossRef Dangas GD, Mehran R, Nikolsky E et al (2011) Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. J Am Coll Cardiol 57:2309–2316PubMedCrossRef
58.
go back to reference Berger PB, Ellis SG, Holmes DR Jr et al (1999) Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 100:14–20PubMedCrossRef Berger PB, Ellis SG, Holmes DR Jr et al (1999) Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 100:14–20PubMedCrossRef
59.
go back to reference Jollis JG, Roettig ML, Aluko AO et al (2007) Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA 298:2371–2380PubMedCrossRef Jollis JG, Roettig ML, Aluko AO et al (2007) Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA 298:2371–2380PubMedCrossRef
60.
go back to reference Ting HH, Rihal CS, Gersh BJ et al (2007) Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 116:729–736PubMedCrossRef Ting HH, Rihal CS, Gersh BJ et al (2007) Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 116:729–736PubMedCrossRef
61.
go back to reference Aguirre FV, Varghese JJ, Kelley MP et al (2008) Rural interhospital transfer of ST-elevation myocardial infarction patients for percutaneous coronary revascularization: the Stat Heart Program. Circulation 117:1145–1152PubMedCrossRef Aguirre FV, Varghese JJ, Kelley MP et al (2008) Rural interhospital transfer of ST-elevation myocardial infarction patients for percutaneous coronary revascularization: the Stat Heart Program. Circulation 117:1145–1152PubMedCrossRef
62.
go back to reference Blankenship JC, Haldis TA, Wood GC, Skelding KA, Scott T, Menapace FJ (2007) Rapid triage and transport of patients with ST-elevation myocardial infarction for percutaneous coronary intervention in a rural health system. Am J Cardiol 100:944–948PubMedCrossRef Blankenship JC, Haldis TA, Wood GC, Skelding KA, Scott T, Menapace FJ (2007) Rapid triage and transport of patients with ST-elevation myocardial infarction for percutaneous coronary intervention in a rural health system. Am J Cardiol 100:944–948PubMedCrossRef
63.
go back to reference Andersen HR, Nielsen TT, Rasmussen K et al (2003) A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349:733–742PubMedCrossRef Andersen HR, Nielsen TT, Rasmussen K et al (2003) A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349:733–742PubMedCrossRef
64.
go back to reference Chakrabarti A, Krumholz HM, Wang Y, Rumsfeld JS, Nallamothu BK (2008) Time-to-reperfusion in patients undergoing interhospital transfer for primary percutaneous coronary intervention in the U.S: an analysis of 2005 and 2006 data from the National Cardiovascular Data Registry. J Am Coll Cardiol 51:2442–2443PubMedCrossRef Chakrabarti A, Krumholz HM, Wang Y, Rumsfeld JS, Nallamothu BK (2008) Time-to-reperfusion in patients undergoing interhospital transfer for primary percutaneous coronary intervention in the U.S: an analysis of 2005 and 2006 data from the National Cardiovascular Data Registry. J Am Coll Cardiol 51:2442–2443PubMedCrossRef
65.
go back to reference Blankenship JC, Scott TD, Skelding KA et al (2011) Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. J Am Coll Cardiol 57:272–279PubMedCrossRef Blankenship JC, Scott TD, Skelding KA et al (2011) Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. J Am Coll Cardiol 57:272–279PubMedCrossRef
Metadata
Title
Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus
Authors
S. Michael Gharacholou
Brenda J. Larson
Christian C. Zuver
Ryan J. Wubben
Giorgio Gimelli
Amish N. Raval
Publication date
01-07-2012
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2012
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-012-0744-4

Other articles of this Issue 1/2012

Journal of Thrombosis and Thrombolysis 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.